Ken Fisher's STRO Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 35,295 shares of Sutro Biopharma, Inc. (STRO) worth $879,198, representing 0.00% of the portfolio. First purchased in 2023-Q2, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Ken Fisher has maintained a strategic position in STRO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 8,161 shares. Largest reduction occurred in Q1 2026, reducing 10 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Sutro Biopharma (STRO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sutro Biopharma (STRO) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -10 | Reduce 0.03% | 35,295 | $24.91 |
| Q4 2025 | +10 | Add 0.03% | 35,305 | $11.57 |
| Q1 2025 | +8,161 | Add 30.08% | 35,295 | $6.51 |
| Q2 2024 | +7,482 | Add 38.07% | 27,134 | $29.30 |
| Q2 2023 | +19,652 | New Buy | 19,652 | $46.50 |
Ken Fisher's Sutro Biopharma Investment FAQs
Ken Fisher first purchased Sutro Biopharma, Inc. (STRO) in Q2 2023, acquiring 19,652 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Sutro Biopharma, Inc. (STRO) for 12 quarters since Q2 2023.
Ken Fisher's largest addition to Sutro Biopharma, Inc. (STRO) was in Q2 2023, adding 19,652 shares worth $913,804.
According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 35,295 shares of Sutro Biopharma, Inc. (STRO), valued at approximately $879,198.
As of the Q1 2026 filing, Sutro Biopharma, Inc. (STRO) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Sutro Biopharma, Inc. (STRO) was 35,305 shares, as reported at the end of Q4 2025.